| |
Tuesday, June 24, 2025 | 1pm ET / 11am PT Join us for this one hour deep dive with a panel of experts and industry leaders to gain valuable insights and guidance on diagnostic and precision medicine testing. Register now.
|
|
Today’s Big NewsJun 17, 2025 |
|
Wednesday June 25, 2025 | 11am ET / 8am PT In this webinar, experts reveal how structured terminology and Real-World Data normalization are transforming patient identification and feasibility — slashing screen failure rates, accelerating site selection, and finally delivering measurable ROI on data spend. Register now.
|
|
| By Fraiser Kansteiner Following HHS secretary Robert F. Kennedy Jr.’s decision last week to purge the CDC’s Advisory Committee on Immunization Practices and appoint his own replacements, the 17 ousted experts are hitting back at the arguments behind the cull. |
|
|
|
By Gabrielle Masson The FDA is introducing a new priority voucher program designed to shorten the drug review process time from 10 to 12 months down to one or two months, according to the agency. |
By Conor Hale A defective speaker resulted in some Dexcom G7, G6 and One CGM users missing audio alarms for unhealthy blood sugar levels. |
By Zoey Becker This year's Pharma Lions awards at the Cannes Lions International Festival of Creativity saw the Grand Prix prize going to to Viatris and its "Make Love Last" Viagra campaign. |
|
Tuesday, June 26, 2025 | 2:30pm ET / 11:30am PT Too many with treatment-resistant depression go undiagnosed and untreated. Join this webinar to see how AI and Real-World Data can transform detection, access, and outcomes in mental health. Register now.
|
|
By Angus Liu The biopharma industry has hit a setback in its ambition to leverage President Donald Trump’s “big, beautiful bill” to amend an Inflation Reduction Act provision currently affecting treatments for rare diseases. |
By James Waldron Eli Lilly confirms its buyout of Verve Therapeutics after reports about the deal were published by the Financial Times Monday. |
By Conor Hale The cart-based Flash 5100 POC system includes AI-powered automation and a large touch screen for rapid, on-demand scanning in high-pressure situations. |
By Zoey Becker Cannes Lions named FCB Health the Healthcare Network of the Year, while AREA 23 is the Healthcare Agency of the Year. Both agencies are arms of IPG Health. |
By Kevin Dunleavy With the FDA's approval of hereditary angioedema preventative treatment Andembry, CSL is ready to take on Takeda’s blockbuster Takhzyro and BioCryst Pharmaceuticals’ fast-rising Orladeyo in a competitive market to treat patients with the rare genetic condition. |
By Gabrielle Masson Antares may be forging ahead with Scorpion's leadership team, but the company is adopting a different approach designed to account for the drastic transformation in both the biotech and macroeconomic environments. |
By Nick Paul Taylor European marketers are feeling the squeeze, with a combination of shrinking budgets, rising targets and tightening compliance requirements piling on the pressure, according to a survey. |
By Kevin Dunleavy Roche and AbbVie have come up short again in their effort to gain an additional indication for their blockbuster blood cancer treatment Venclexta. |
By Darren Incorvaia A federal judge in Massachusetts has ruled that hundreds of grants terminated by the National Institutes of Health must be immediately restored, the latest legal victory for groups challenging the Trump administration’s extreme cuts to federal science funding. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we unpack Fierce Medtech's Fierce 15 and spotlight startups reimagining healthcare. |
|
|---|
|
|
|
Patients need innovative treatments to treat diseases and save lives, but today’s biopharmaceutical development and manufacturing environment presents multiple challenges for biopharma companies. Access this valuable resource for key insights on navigating the complex road to market, including quality standards, regulatory requirements, supply-chain disruptions, and more.
|
|
| WhitepaperWe analyzed ~300 launches to identify the factors most correlated with commercial success & built a framework for peak go-to-market performance. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
